The Use of Immunotherapies in Triple-Negative Breast Cancer

Affecting millions of individuals every year, breast cancer is one of the most prevalent cancer subtypes to impact women worldwide. Triple-negative breast cancer (TNBC), specifically, proves to be one of the most difficult breast cancers to treat. Currently, the use of immunotherapy in TNBC patients is limited primarily to immune checkpoint inhibitors (ICIs) due to a lack of safe and effective alternative options. However, not all patients of the TNBC population respond effectively to ICIs. Therefore, the need for more immunotherapy options is crucial to the survival of many TNBC patients. In this review, we will discuss common immunotherapy options for TNBC patients and their efficacy. We will additionally review the emerging methods of immunotherapy use in TNBC patients and their potential future impacts.